Table 2.
Baseline characteristics of individuals eligible for the emulation of a target trial of thromboprophylaxis in COVID-19 patients, Hospital Universitario La Paz, Madrid, Spain; March 16–April 15, 2020
| Variable | Increased baseline thrombotic riskb |
|
|---|---|---|
| Yes (N = 781) | No (N = 503) | |
| Age (yr), median (IQR) | 70 (59, 81) | 61.0 (51.0, 76.0) |
| Gender (% Male) | 60.2 | 47.1 |
| Immigrant (%) | 18.8 | 31.2 |
| Disability (%)a | 7.8 | 6.6 |
| Suspected hospital acquisition (%) | 15.1 | 16.7 |
| Chronic heart disease (%) | 16.3 | 14.11 |
| High blood pressure (%) | 52.1 | 42.1 |
| Diabetes mellitus (%) | 22.2 | 18.5 |
| Obesity (%) | 17.2 | 18.7 |
| Dyslipidemia (%) | 37.6 | 36.6 |
| Active smoking (%) | 7.4 | 4.4 |
| Chronic kidney disease (%) | 10.8 | 2.8 |
| Malignant neoplasms (%) | 11.1 | 5.9 |
| Hematological disease (%) | 52.5 | 6.2 |
| Charlson Comorbidity Index, median (IQR) | 3 (2, 5) | 2 (1, 4) |
| CURB-65 score, median (IQR) | 1 (0, 2) | 1 (0, 1) |
| Heart rate at admission, bpm, median (IQR) | 91 (80, 104) | 91 (78, 105) |
| Admission before/after April 5 (%) | 85.3 | 84.3 |
| D-dimer at baseline | 1,088.5 (609.5; 2,159.5) | 540.0 (368.0, 802.0) |
Abbreviations: IQR, interquartile range.
a
Disability as indicated by a Katz Basic Activities of Daily Living Score ≤ 2.
b
C-reactive protein >150 mg/dL, D-dimer >1,500 ng/mL, ferritin >1,000 μg/L, or lymphocyte count <800/mL.